Overview

TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer

Status:
Active, not recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

This study evaluates efficacy of TAK- 228 and TAK- 117 followed by cisplatin and nab paclitaxel in patients with metastatic triple negative breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Baylor Research Institute

Collaborator:

Takeda

Treatments:

Albumin-Bound Paclitaxel
Cisplatin
Paclitaxel
Serabelisib